First-Of-Kind Treatments Win Funding in England & Wales
NICE Fast-Tracks Novartis’s Beovu
Executive Summary
Treatments for non-small cell lung cancer, Pompe disease and two main forms of ANCA-associated vasculitis from Roche, Sanofi and CSL Vifor respectively are to be made available for patients on the National Health Service.
You may also be interested in...
Vision Loss Drug Vabysmo Secures English Funding; Oxlumo & Tavneos Deemed Too Pricey
Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.
‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount
Health technology assessment institute NICE has reversed its provisional rejection of Oxlumo for treating the rare disease, primary hyperoxaluria type 1.
New EU Filings
Sugemalimab, from CStone Pharmaceuticals/EQRx, for use in combination with chemotherapy as first-line treatment for metastatic non-small cell lung cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.